Novartis sees Alcon helping to drive group growth as reimbursements falls 10%
This article was originally published in Scrip
Novartis has issued an update on the growth prospects of the group, and of the Alcon eye care business it acquired for around $52 billion in staggered transactions completed in April. It expects new product launches, along with its business in fast-growing emerging markets, to offset significant patent expiries (for Femara, Diovan and Zometa) over the next couple of years and drive sales growth, with improved productivity, efficiency savings, economies of scale and better procurement enabling operating income to grow faster than sales.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.